166 related articles for article (PubMed ID: 37702560)
1. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice.
Gillis NE; Cozzens LM; Wilson ER; Smith NM; Tomczak JA; Bolf EL; Carr FE
Endocrinology; 2023 Aug; 164(10):. PubMed ID: 37702560
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.
Bolf EL; Gillis NE; Davidson CD; Rodriguez PD; Cozzens L; Tomczak JA; Frietze S; Carr FE
Mol Cancer Res; 2020 Oct; 18(10):1443-1452. PubMed ID: 32554601
[TBL] [Abstract][Full Text] [Related]
3. Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity.
Zhu X; Zhao L; Doolittle WKL; Cheng SY
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36939877
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cancer stem cell activity by thyroid hormone receptor β.
Lee WK; Zhu X; Park S; Zhu YJ; Zhao L; Meltzer P; Cheng SY
Oncogene; 2022 Apr; 41(16):2315-2325. PubMed ID: 35256781
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Hormone Receptor Beta Inhibits PI3K-Akt-mTOR Signaling Axis in Anaplastic Thyroid Cancer via Genomic Mechanisms.
Davidson CD; Bolf EL; Gillis NE; Cozzens LM; Tomczak JA; Carr FE
J Endocr Soc; 2021 Aug; 5(8):bvab102. PubMed ID: 34258492
[TBL] [Abstract][Full Text] [Related]
6. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
7. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
8. Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Doolittle WKL; Zhao L; Cheng SY
Thyroid; 2022 Aug; 32(8):937-948. PubMed ID: 35822558
[No Abstract] [Full Text] [Related]
9. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
10. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer.
Patel PN; Yu XM; Jaskula-Sztul R; Chen H
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S497-504. PubMed ID: 24419754
[TBL] [Abstract][Full Text] [Related]
11. Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.
Park JW; Zhao L; Willingham MC; Cheng SY
Mol Carcinog; 2017 Feb; 56(2):489-498. PubMed ID: 27254276
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth.
Yu XM; Jaskula-Sztul R; Ahmed K; Harrison AD; Kunnimalaiyaan M; Chen H
Mol Cancer Ther; 2013 Jul; 12(7):1276-87. PubMed ID: 23594881
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells.
Kocdor MA; Cengiz H; Ates H; Kocdor H
Anticancer Agents Med Chem; 2019; 19(15):1887-1898. PubMed ID: 31584382
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Kawamura Y; Saijo K; Imai H; Ishioka C
Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models.
Kim WG; Zhao L; Kim DW; Willingham MC; Cheng SY
Thyroid; 2014 Feb; 24(2):260-9. PubMed ID: 23731250
[TBL] [Abstract][Full Text] [Related]
16. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer.
Carr FE; Tai PW; Barnum MS; Gillis NE; Evans KG; Taber TH; White JH; Tomczak JA; Jaworski DM; Zaidi SK; Lian JB; Stein JL; Stein GS
Endocrinology; 2016 Aug; 157(8):3278-92. PubMed ID: 27253998
[TBL] [Abstract][Full Text] [Related]
18. The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.
Bolf EL; Gillis NE; Barnum MS; Beaudet CM; Yu GY; Tomczak JA; Stein JL; Lian JB; Stein GS; Carr FE
Horm Cancer; 2020 Feb; 11(1):34-41. PubMed ID: 31865591
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
20. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
